Norway's Navamedic Q3 revenue drops on weakness in prescription drugs and consumer health business

Overview

• Norway healthcare products provider's Q3 revenue fell 13.2% yr/yr

• Gross margin improved to 39.5% from 37.5% a year earlier

• Revenue decline driven by lower Prescription Drugs and Consumer Health sales, plus negative currency impact

Outlook

• Navamedic expects improved EBITDA in 2026 compared to 2025

• Company expects 2026 revenue to be somewhat lower than 2025 on constant currency basis

• Company sees improved gross margins in 2026 due to favourable product mix and operational efficiencies

Result Drivers

• MYSIMBA SALES DROP - Co said lower sales of Mysimba, mainly due to wholesaler purchasing patterns, contributed to decreased Prescription Drugs revenue

• DISCONTINUED BRANDS - Co said discontinued brands reduced Prescription Drugs revenue compared to last year

• CONSUMER HEALTH WEAKNESS - Co said Consumer Health revenue fell due to increased competition for Modifast, campaign timing for ThermaCare, and phase-out of GeloRevoice

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Navamedic ASA is NOK21.00, about 56.7% above its October 28 closing price of NOK13.40

• The stock recently traded at 60 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads

• Oct 28 - Norway's Telenor Q3 service revenue rises, maintains 2026 forecast

• Oct 26 - Medifast Q3 revenue falls on fewer active earning coaches

• Oct 28 - Norway's Borregaard Q3 EBITDA hits record, beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)